Vaccine trial dropouts pose dilemma for manufacturers16/12/2020|2min
Vaccine trial dropouts are posing a dilemma for companies creating coronavirus vaccines.
INOVIO vaccine trial participant Brandon Kenig has said he would like to receive an approved vaccine when one is released and by doing so, will need to drop out of the INOVIO trials.
Mr Kenig has been involved in the INOVIO vaccine phase one trials since the spring; the trial includes 48 people who received vaccines.
Principle Investigator Dr John Ervin said participant dropouts are a dilemma he’s anticipated since the trials began.
“These studies are voluntary, and I think we have to have what’s best for the individual as our main interest,’ Mr Ervin said.